Concepedia

Randall E. Millikan

RE

Statistics

Publications

54

Citations

6.3K

H-Index

42

Active since

1987

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Spanish Oncology Genitourinary Group

Essentia Health

Randall E. Millikan is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and chemotherapy.

Publications per year

1987–2016

54

Publications

54

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Ana M. Aparicio, Andrea Harzstark, Paul G. Corn et al. · Clinical Cancer Research · 2013 · 466 citations · Full text

, , +16

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Christos N. Papandreou, Danai Daliani, Darrell Nix et al. · Journal of Clinical Oncology · 2004 · 437 citations · Full text

, , +12

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

Shi‐Ming Tu, Randall E. Millikan, Bayabel Mengistu et al. · The Lancet · 2001 · 395 citations

, , +16

Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center Experience

Arlene O. Siefker‐Radtke, Jason Gee, Yu Shen et al. · The Journal of Urology · 2003 · 305 citations

, , +7

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

David J. McConkey, Woonyoung Choi, Yu Shen et al. · European Urology · 2015 · 277 citations · Full text

, , +15

1–5 of 54